Skip to main content

Fluocinolone ophthalmic Pregnancy and Breastfeeding Warnings

Brand names: Iluvien, Retisert, Yutiq

Medically reviewed by Drugs.com. Last updated on Oct 6, 2023.

Fluocinolone ophthalmic Pregnancy Warnings

Use should be avoided.

US FDA pregnancy category: C

Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Fluocinolone ophthalmic Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-The effects in the nursing infant are unknown.
-Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.

See references

See also

References for pregnancy information

  1. (2005) "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb Americas, Inc.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

References for breastfeeding information

  1. (2005) "Product Information. Retisert (fluocinolone ophthalmic)." Bausch and Lomb Americas, Inc.
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer